CD70 and neoplasm: Strikingly, AlloCAR70-NKT cells were capable of killing both CD70+ and CD70− tumor cells, with enhanced efficacy toward CD70+ targets, indicating both CAR-dependent and CAR-independent mechanisms (Figures 3D and S3C).